Navigation Links
Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
Date:10/6/2010

SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, November 3, 2010 at 4:30 p.m. ET to review third quarter financial results.  

Access to the discussion may be obtained as follows: Time:

4:30 PM ET / 1:30 PM PTDate:

November 3, 2010Dial-in:

1-866-730-5769 (domestic) or +1-857-350-1593 (international); conference pass code: 35737817Webcast:

www.dendreon.com (homepage and investor relations section) A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1- 888-286-8010 or +1-617-801-6888 for international callers; the conference ID number is 97336729. The replay will be available from 7:30 pm ET on Wednesday, November 3rd until 11:59 pm ET on Wednesday, November 10th.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About DendreonDendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Research and Markets ... DNA Diagnostics Market (Product types, Application, Technology, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. This new ... end users and Geography) Global Size, Industry Analysis, ...
(Date:10/22/2014)... 2014 The Americas Inorganic Refrigerants ... market in Americas with analysis and forecast of ... Americas Inorganic Refrigerants Market report, to get an ... provides a glimpse of the segmentation in the ... various tables and figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html ...
(Date:10/22/2014)... October 21, 2014 Shimadzu Scientific Instruments ... data tool for the pain management and clinical markets. ... processing and review by allowing users to highlight and ... , QuantAnalytics allows analysts to filter results by ... data processing by eliminating the need to sift through ...
(Date:10/22/2014)... 22, 2014 WriteResult, LLC – ... has been working with a team of researchers from ... Farms Community Farming Collaborative to provide electronic questionnaire data ... The study, which started in May, aims to evaluate ... participants weekly exposure to and participation in urban agriculture ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3
... offers multiple diagnostic modalities on a single system ... ... physicians and administrators, SAN DIEGO, March 28 Volcano ... intravascular,ultrasound (IVUS), functional measurement (FM) and Optical Coherence,Tomography (OCT) products ...
... Vical Incorporated,(Nasdaq: VICL ) today announced the ... 27, 2008, of a New Drug Application (NDA) ... for its angiogenesis,product candidate, Collategene, for treatment of ... deliver a gene encoding hepatocyte,growth factor (HGF), a ...
... Ill. Scientists have developed a new form of ... shapes such as spheres, body parts and aircraft wings, ... types of extreme mechanical deformations, without a reduction in ... used in such applications because it is intrinsically brittle ...
Cached Biology Technology:Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 2Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 3Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 4Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 5Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product 2Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product 3Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product 4Foldable and stretchable, silicon circuits conform to many shapes 2Foldable and stretchable, silicon circuits conform to many shapes 3
(Date:10/22/2014)... BEDFORD, Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its third quarter ... quarter of 2014 was $6.0 million, an increase of 40% ... Operating income in the third quarter of 2014 was $4.1 ... 2013. Higher operating income in the current three month period ...
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... GenWay Clinical Laboratory, a US-based diagnostic company with ... in their laboratory and now offers this testing service. ... a small blood sample from the patient in order ... their serum. This unique and proprietary test formula ...
... researchers have so far won 19 grants worth a total ... American Recovery and Reinvestment Act. The grants range from ... could produce biological hydrocarbons for biofuels to $600,000 for a ... how the Ebola virus can inhibit a body,s antiviral response. ...
... Japanese research group led by Professor Junichi Nabekura in ... after cerebral stroke in one side of the mouse ... circuits to recuperate from damaged neural function. The Japan ... report their finding in Journal of Neuroscience , ...
Cached Biology News:Iowa State faculty attract $4.8 million in American Recovery and Reinvestment Act grants 2Iowa State faculty attract $4.8 million in American Recovery and Reinvestment Act grants 3Iowa State faculty attract $4.8 million in American Recovery and Reinvestment Act grants 4
... Virus Reverse Transcriptase (M-MLV RT) is an RNA-dependent ... synthesis with long messenger RNA templates (>5kb). The ... of M-MLV and consists of a single subunit ... H activity of M-MLV RT is weaker than ...
... 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is ... (8-iso PGF2α), in rabbits, monkeys and ... product of non-specific lipid peroxidation. In ... 8-isoprostane is converted primarily to metabolites ...
... The European Collection of Cell Cultures ... the West of the West of England, ... for the quality control of HER2, oestrogen ... of paraffin wax sections of formalin fixed, ...
kismet (dK-20)...
Biology Products: